Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Summit Therapeutics Inc

SMMT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$13.35

▼ -4.64%

Market Cap $10.65B · Vol 2.40M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.65B

Large Cap

Div Yield

N/A

EPS Growth

+17.09%

YoY

RSI (14)

51.98

Momentum

Beta

-1.25

vs Market

52W High

$30.05

55.57% below

52W Low

$12.25

8.98% above

Volume

2.40M

Avg 1.30M

P/B

20.58

Price-to-book

ROE

-206.12%

Return on equity

Free Float

19.11%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Summit Therapeutics Inc (SMMT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SMMT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.37%

-13.70%

-26.41%

-10.76%

YTD

-23.67%

-49.53%

+595.31%

+68.56%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,079,586,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-206.12%
ROA · ROIC	-181.94% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	20.58
P/FCF	N/A
EPS Growth	+17.09%
Outstanding Shares	797.75M

Technical Indicators

50-Day SMA	$14.24
200-Day SMA	$16.74
RSI (14)	51.98
Beta	-1.25
52-Week High	$30.05
52-Week Low	$12.25

Volume Today	2.40M
Avg Daily Volume (30D)	1.30M
Relative Volume	1.84x
Volatility (10D)	63.72
Volatility (30D)	64.23
Free Float	19.11%

Analyst Consensus

BUY

Current Price $13.35

Mean Target $28.34

52W Low$12.25 52W High$30.05

Current

Target

$12.25 $30.05

Current Analyst target

+112.31% upside potential · 18 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00X3GQL94

ISINUS86627T1088

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 19, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.